Area of research
Hematology · Molecular Biology
Research interest
Research interests include Multiple Myeloma Research and Treatments, Protein Degradation and Inhibitors, Peptidase Inhibition and Analysis, and Cancer Treatment and Pharmacology.
Phase 3 Study of Teclistamab (Tec) in Combination with Lenalidomide (Len) and Tec Alone Versus Len Alone in Newly Diagnosed Multiple Myeloma (NDMM) As Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT): Safety Run-in (SRI) Results from the Majestec-4/EMN30 Trial
Germline predisposition in multiple myeloma
Management of hemophagocytic lymphohistiocytosis (HLH) associated with chimeric antigen receptor T-cell (CAR-T) therapy using anti-cytokine therapy: an illustrative case and review of the literature
Updated Results from the Phase I CRB-402 Study of Anti-Bcma CAR-T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma: Correlation of Expansion and Duration of Response with T Cell Phenotypes
Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma
Racial differences in treatment and outcomes in multiple myeloma: a multiple myeloma research foundation analysis
Results from a multidisciplinary clinic guided by geriatric assessment before stem cell transplantation in older adults
Updated Results from an Ongoing Phase 1 Clinical Study of bb21217 Anti-Bcma CAR T Cell Therapy
Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma
Synergistic Myeloma Cell Death via Novel Intracellular Activation of Caspase-10–Dependent Apoptosis by Carfilzomib and Selinexor
Proteomic profiling of naïve multiple myeloma patient plasma cells identifies pathways associated with favourable response to bortezomib‐based treatment regimens
Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma
The mechanistic role of DNA methylation in myeloid leukemogenesis